Olfr895 Inhibitors
Olfr895, a member of the olfactory receptor family in Mus musculus (house mouse), plays a crucial role in the early stages of olfaction. These olfactory receptors, including Olfr895, are essential for detecting odorant molecules in the nasal environment, initiating a complex cascade of events that ultimately leads to the perception of specific odors. Olfr895 shares the structural characteristics of olfactory receptors, characterized by a 7-transmembrane domain, and belongs to the family of G-protein-coupled receptors (GPCRs) encoded by single coding-exon genes.
Inhibition of Olfr895 primarily occurs through the modulation of key components within the olfactory signaling pathway. While direct inhibitors specifically binding to Olfr895 may be limited, indirect inhibition is achieved by targeting elements of the pathway. Chemical compounds can influence Olfr895 function by acting on essential components such as adenylyl cyclase, kinases like PKA, calcium channels, MAPK pathways, and phospholipase C (PLC). These compounds indirectly disrupt olfactory receptor signaling, potentially leading to the down-regulation of Olfr895 function and affecting the perception of specific odors in house mice. The intricate interplay of these inhibitors with the complex signaling networks associated with olfaction highlights the dynamic nature of olfactory perception and the potential for precise modulation of Olfr895 and related receptors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a potent MEK inhibitor that can indirectly modulate the MAPK pathway. By targeting this pathway, it may affect Olfr895 indirectly, as MAPK signaling has crosstalk with olfactory receptor signaling, potentially leading to changes in the receptor's function and odor perception. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K8644 is a calcium channel agonist, and its antagonist counterpart can block calcium channels. By inhibiting calcium influx, it indirectly disrupts olfactory receptor signaling, potentially down-regulating Olfr895 function and the perception of specific odors. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
SQ 22536 is an adenylate cyclase inhibitor, indirectly influencing Olfr895 by reducing cAMP production. Inhibition of adenylate cyclase can lead to down-regulation of Olfr895-mediated signal transduction and odor perception. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
KN-62 is a potent inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII). Its indirect impact on Olfr895 may occur by inhibiting CaMKII, potentially influencing olfactory receptor signaling and the receptor's response to specific odors. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis Toxin is known to inhibit G-protein signaling, including the type of G proteins involved in olfactory receptor signaling. By blocking G protein activity, it may indirectly down-regulate Olfr895 function and affect the perception of specific odors. | ||||||
Phytic acid solution | 83-86-3 | sc-205806 sc-205806A | 100 ml 500 ml | $151.00 $515.00 | ||
Phytic acid solution is a naturally occurring molecule that can influence cellular signaling, including pathways related to olfactory receptors. Its effects on intracellular signaling may indirectly affect Olfr895 function and odor perception by interfering with specific signaling events. | ||||||
Gallein | 2103-64-2 | sc-202631 | 50 mg | $85.00 | 20 | |
Gallein is a G protein-coupled receptor (GPCR) inhibitor that can indirectly modulate olfactory receptor signaling by affecting GPCR function. By interfering with GPCR signaling pathways, it may have an impact on Olfr895 and odor perception by disrupting downstream events in the receptor's signaling cascade. | ||||||